The Reserve Bank of India (RBI) has restricted the Foreign Institutional Investors (FIIs)/Foreign Portfolio Investors (FPIs) in Claris Lifesciences as the foreign investors have crossed the overall limit of 24% of paid-up capital of the company.
RBI monitors ceilings on FII/NRI/PIO investments in Indian companies on a daily basis.
Claris Lifesciences is a multi-business enterprise and the holding company of Claris Injectables, a wholly- owned subsidiary dealing in Speciality Injectables business and has a minority stake in Claris Otsuka.
